A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

AstraZeneca has warned that countries must buy more of its cutting-edge medicines or jobs and investment will shift abroad.

AstraZeneca and Daiichi Sankyo ... endocrine therapy in the metastatic setting. Enhertu is already approved for patients with HR+, HER2-low breast cancer after endocrine therapy based on the ...

Nice, the NHS spending watchdog, last year blocked AstraZeneca’s breast cancer treatment Enhertu, prompting widespread criticism from cancer charities. The medicine has been found to double the ...

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

In recent years, the treatment landscape of HR+/HER2−ve breast cancer has completely changed with the introduction of particularly active targeted drugs, from CDK4/6 inhibitors, mTOR inhibitors, and ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

AstraZeneca said today it may face a fine of up to $8m over suspected unpaid import taxes in China as the drugmaker works to ...

Despite AstraZeneca’s falling share price today, this writer believes the London-listed pharmaceutical giant could be worth a ...